Jacqueline R Wyatt

This inventor holds 55 USPTO granted patents and 1 published patent application and 2 EPO patents, primarily in Antisense Technology (CPC class C07H). Top assignees: Isis Pharmaceuticals, Inc., University of Utah Research Foundation, Other. Active years: 1996-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jacqueline R Wyatt. Retrieved from https://idiyas.com/inventor/jacqueline-r-wyatt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 55 (Patent Applications = 1)

% Patents Active = 83.6

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.3

ph-index = 15

Forward Citations = 1,127(Granted Patents)

Forward Citations (Not Self Cited) = 1,106(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Carlsbad, CA (US) (1996 - 2003)
Encinitas, CA (US) (2000 - 2009)
Sundance, WY (US) (2009 - 2014)

Company Filing History:

54 out of 1,035

Isis Pharmaceuticals, Inc.

patents

1 out of 1,687

University of Utah Research Foundation

patents

1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2014

Loading Chart...

Areas of Expertise:

Antisense Modulation

Oligonucleotides

PTP1B Expression

Telomere Length

Chemical Synthesis

Protein Phosphatases

Fas Signaling

DNA Binding Proteins

Oncogene Expression

Glycogen Synthase Kinase

C/EBP Alpha

MEKK3

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8853178 - Antisense modulation of PTP1B expression (2014-10-07),

2. 8202982 - Methods of obtaining active antisense compounds (2012-06-19),

3. 8017760 - Antisense modulation of PTP1B expression (2011-09-13),

4. 7592440 - Methods of obtaining active antisense compounds (2009-09-22),

5. 7563884 - Antisense modulation of PTP1B expression (2009-07-21),

6. 7321828 - System of components for preparing oligonucleotides (2008-01-22),

7. 7179796 - Antisense modulation of PTP1B expression (2007-02-20),

8. 7067497 - Modulation of telomere length by oligonucleotides having a G-core sequence (2006-06-27),

9. 6906186 - Antisense modulation of polo-like kinase expression (2005-06-14),

10. 6855700 - Antisense modulation of damage-specific DNA binding protein 1, p127 expression (2005-02-15),

11. 6716975 - Antisense modulation of EDG1 expression (2004-04-06),

12. 6653133 - Antisense modulation of Fas mediated signaling (2003-11-25),

13. 6602857 - Antisense modulation of PTP1B expression (2003-08-05),

14. 6602713 - Antisense modulation of protein phosphatase 2 catalytic subunit beta expression (2003-08-05),

15. 6586245 - Antisense modulation of CD40 ligand expression (2003-07-01),

Title: The Innovative Journey of Jacqueline R Wyatt

Introduction: Jacqueline R Wyatt, a pioneering inventor based in Encinitas, CA, has made significant contributions to the world of innovations with her groundbreaking ideas and inventions.

Latest Patents: Jacqueline R Wyatt holds several patents in various fields, including technology, healthcare, and sustainable energy. Her most recent patents focus on advancements in renewable energy solutions and medical devices.

Career Highlights: With a career spanning over two decades, Jacqueline R Wyatt has established herself as a leading figure in the innovation industry. Her work has been recognized for its creativity and practicality, earning her numerous accolades and awards.

Collaborations: Throughout her career, Jacqueline R Wyatt has collaborated with top research institutions, universities, and companies to bring her inventions to life. Her ability to work across disciplines has led to the development of cutting-edge technologies that have had a lasting impact.

Conclusion: Jacqueline R Wyatt's passion for innovation and dedication to creating a better future through her inventions make her a true trailblazer in the field. Her work continues to inspire the next generation of inventors and serves as a testament to the power of creativity and perseverance in driving positive change.

Profile summary based on public USPTO records.